Chronic kidney disease, heart failure and anemia

Canadian Journal of Cardiology

Volumn 24, Issue SUPPL. B, 2008, Pages 22B-24B

  Virani, Sean A ^a   Khosla, Amit ^a   Levin, Adeera ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anemia; Chronic kidney disease; EPO; Heart failure

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BRAIN NATRIURETIC PEPTIDE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MORBIDITY; MORTALITY; OXYGEN CONSUMPTION; PROGNOSIS; UNSPECIFIED SIDE EFFECT;

EID: 48749099994     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0828-282x(08)71026-2     Document Type: Article

References (41)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
2. Canadian Organ Replacement Register Annual Data Report (2007). (Version current at May 22, 2008).
3. Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006;113:2713-23.
4. Wali RK, Henrich WL. Chronic kidney disease: a risk factor for cardiovascular disease. Cardiol Clin 2005;23:343-62.
5. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;39:955-62.
6. Rahman M, Brown CD, Coresh J, et al. The prevalence of reduced glomerular filtration rare in older hypertensive patients and its association with cardiovascular disease: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Arch Intern Med 2004;164:969-76.
7. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2006;151:492-500.
8. Androne AS, Katz SD, Lund L, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003;107:226-9.
9. Anand I, McMurray J, Whitmore J, et al. Anemia and Its Relationship to Clinical Outcome in Heart Failure. Circulation 2004;110:149-54.
10. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39:1780-6.
11. Sharma R, Francis D, Pitt B, et al. Hemoglobin predicts survival in patients with chronic heart failure: A sub-study of the ELITE II trial. Eur Heart J 2004;25:1021-8.
12. Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: Results from Val-HeFT. Circulation 2005;112:1121-7.
13. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes. Circulation 2003;107:223-5.
14. Levin A, Djurdjev O, Duncan J, et al. Haemoglobin at time of referral prior to dialysis predicts survival: An association of haemoglobin with long-term outcomes. Nephrol Dial Transplant 2006;21:307-12.
15. Ksiazek A, Zaluska WT, Ksiazek P. Effect of recombinant human erythropoietin on adrenergic activity in normotensive hemodialysis patients. Clin Nephrol 2001;56:104-9.
16. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36.
17. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999;55:808-20.
18. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999-1007.
19. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 2001;12:2759-67.
20. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Eng J Med 1998;339:584-90.
21. Furuland H, Linde T, Ahlmen J, et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;18:353-61.
22. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325-35.
23. Moreno F, Sanz-Guajardo D, López-Gómez JM, Jofre R, Valderrábano F. IIncreasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000;11:335-42.
24. McMahon LP, McKenna MJ, Sangkabutra T, et al. Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol Dial Transplant 1999;14:1182-7.
25. Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005;16:2180-9.
26. Roger SD, McMahon LD, Clarkson A, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol 2004;15:148-56.
27. Levin A, Djurdjev O, Thompson C, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005;46:799-811.
28. Macdougall IC, Temple RM, Kwan JT. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Nephrol Dial Transplant 2007;22:784-93.
29. Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007;49:194-207.
30. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-82.
31. Singh AK, Szczech L, Kezhen LT, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
32. Levin A, Djurdjev O, Ravani P, Macdougall I, MacMahon L. Meta-analysis of individual patient data from randomized trials with epoetin alfa therapy: Progression of kidney disease. American Society of Nephrology Renal Week, San Francisco, California, 2007. (Conference presentation)
33. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target hemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 2007;369:381-8.
34. Bansal N, Tighiouart MS, Weiner D, et al. Anemia as a risk factor for kidney function decline in individuals with heart failure. Am J Cardiology 2007;99:1137-42.
35. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure. The Prospective Amlodipine Survival Evaluation (PRAISE). J Am Coll Cardiol 2003;41:1933-9.
36. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 2005;149:391-401.
37. Palazzuoli A, Silverberg D, Iovine F, et al. Erythropoietin improves anemia, exercise tolerance and renal function, and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006;152:1096.e9-15.
38. Palazzuoli A, Silverberg D, Iovine F, et al. Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007;154:645.e9-e15.
39. Silverberg D, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J Am Coll Cardiol 2001;37:1775-80.
40. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107:294-299.
41. Clinical Trials. (Version current at November 15, 2007).